Analysts’ Weekly Ratings Changes for Boston Scientific (BSX)

A number of research firms have changed their ratings and price targets for Boston Scientific (NYSE: BSX):

• 5/19/2026 – Boston Scientific had its price target lowered by Robert W. Baird from $78.00 to $75.00. They now have an “outperform” rating on the stock.
• 5/18/2026 – Boston Scientific had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $77.00 price target on the stock.
• 5/18/2026 – Boston Scientific had its price target lowered by Bank of America Corporation from $105.00 to $68.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Boston Scientific had its “buy” rating reaffirmed by BTIG Research. They now have a $80.00 price target on the stock.
• 5/13/2026 – Boston Scientific was downgraded by Weiss Ratings from “hold (c)” to “hold (c-)”.
• 4/29/2026 – Boston Scientific was downgraded by Daiwa Securities Group Inc. from “strong-buy” to “hold”.
• 4/23/2026 – Boston Scientific had its price target lowered by Royal Bank Of Canada from $105.00 to $100.00. They now have an “outperform” rating on the stock.
• 4/23/2026 – Boston Scientific was given a new $90.00 price target by Oppenheimer Holdings, Inc..
• 4/23/2026 – Boston Scientific had its price target lowered by Canaccord Genuity Group Inc. from $109.00 to $71.00. They now have a “buy” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Wells Fargo & Company from $94.00 to $75.00. They now have an “overweight” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Barclays PLC from $124.00 to $96.00. They now have an “overweight” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Needham & Company LLC from $97.00 to $77.00. They now have a “buy” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Robert W. Baird from $86.00 to $78.00. They now have an “outperform” rating on the stock.
• 4/23/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $90.00 to $85.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Boston Scientific had its price target lowered by The Goldman Sachs Group, Inc. from $87.00 to $84.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Boston Scientific had its price target lowered by BTIG Research from $90.00 to $80.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Boston Scientific had its price target lowered by Jefferies Financial Group Inc. from $110.00 to $100.00. They now have a “buy” rating on the stock.
• 4/22/2026 – Boston Scientific had its price target lowered by Barclays PLC from $124.00 to $100.00. They now have an “overweight” rating on the stock.
• 4/21/2026 – Boston Scientific had its price target lowered by Stifel Nicolaus from $90.00 to $85.00. They now have a “buy” rating on the stock.
• 4/15/2026 – Boston Scientific had its price target lowered by Truist Financial Corporation from $92.00 to $90.00. They now have a “buy” rating on the stock.
• 4/13/2026 – Boston Scientific had its price target lowered by Mizuho from $115.00 to $90.00. They now have an “outperform” rating on the stock.
• 4/7/2026 – Boston Scientific had its price target lowered by Citigroup Inc. from $94.00 to $87.00. They now have a “buy” rating on the stock.
• 3/30/2026 – Boston Scientific had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $115.00 price target on the stock.
• 3/30/2026 – Boston Scientific had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $88.00 price target on the stock, down from $97.00.
• 3/30/2026 – Boston Scientific had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $97.00 price target on the stock.
• 3/28/2026 – Boston Scientific was downgraded by Wall Street Zen from “buy” to “hold”.
• 3/27/2026 – Boston Scientific had its price target lowered by The Goldman Sachs Group, Inc. from $98.00 to $93.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the purchase, the director owned 1,770 shares in the company, valued at $99,987.30. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 9,800 shares of company stock worth $554,012 in the last ninety days. 0.34% of the stock is owned by insiders.

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.